A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
Completed
LEO Pharma
Phase 3
2012-03-01
The purpose of this trial is to compare the rate of complete clearance of actinic keratosis
(AK) using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy
alone.
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
Completed
LEO Pharma
Phase 1/Phase 2
2013-02-01
The purpose of this study is to determine if the new vehicle formulations containing ingenol
mebutate are as safe and effective as Picato® gel 0.05% (it's current vehicle formulation)
when applied to AK lesions on the forearm for two consecutive days.
Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
Completed
LEO Pharma
2013-07-01
Assessment of treatment success and quality of life in patients with actinic keratoses under
therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.
Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis
Completed
LEO Pharma
N/A
2014-05-01
Background: 5% 5-fluorouracil cream (5-FU) is a well-established treatment for actinic
keratosis (AK) and ingenol mebutate gel (IMB) is a new topical field therapy.
Objective: To compare tolerability and safety of IMB with 5-FU for the treatment of facial
AKs.
Methods: Open-label, prospective, randomized, controlled clinical trial with 100 patients
with AKs within 25-cm2 contiguous field on the face. IMB was applied daily for three
consecutive days. 5-FU was applied twice a day for four weeks. Treatment effect was evaluated
at baseline and on days 2, 3, 4, 8, 15, 22, 29, 36 and 43, considering ITT populations.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.